Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive July 1, 2012 William Looney	The Learning Curve In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises; change for pharma is here and it's good.
Pharmaceutical Executive December 1, 2010 William Looney	In Through the Out Door The end of anther year is an appropriate time to highlight the march of time and the transitions that accompany it in Europe and in China.
Pharmaceutical Executive October 1, 2014 Leela Barham	The Gate Keeper Dr. David Haslam, Chair of the UK's National Institute of Health and Care Excellence, discusses what the quantitative calculations of value mean to patient access in today's messy world of real-time medicine.
Pharmaceutical Executive October 1, 2014 William Looney	IDEAlogue for Innovation Professor Fabio Pammolli, a leading European economist and policy advisor to the key EU institutions, outlines the current dilemma facing health and pharma regulators in Europe today.
Pharmaceutical Executive August 1, 2011 William Looney	Paying for Health -- The Right Way What Big Pharma fails to see is how engagement in health policy is the biggest of reputation builders
Nursing Management April 2012 Gloria Kersey-Matusiak	Culturally competent care: Are we there yet? What exactly is culturally competent care, and how can you use it to lessen healthcare disparities among your patients?
Pharmaceutical Executive January 1, 2012 William Looney	The Well of Engagement We sometimes forget that the business of healthcare is also the source of a huge opportunity: improving the human condition.
Pharmaceutical Executive December 1, 2011 William Looney	The Medicines Adherence Challenge Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma, but is it? An expert round table examines how best to make progress and agree on some practical steps for incorporation in the campaign agenda.
Pharmaceutical Executive January 1, 2012 William Looney	Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Pharmaceutical Executive July 1, 2012	Emerging Pharma Leaders 2012 Meet 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history by doing better with less while tapping new opportunities from science and technology to build competitive scale?
Pharmaceutical Executive April 1, 2014 William Looney	The Trials of Commerce Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.
Pharmaceutical Executive September 1, 2011 Richard Barker	Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
Pharmaceutical Executive January 21, 2014 Comer & Upton	Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday.
Pharmaceutical Executive October 1, 2011	Patient Advocacy: The Last 30 Years The rise of advocacy groups has helped patients find their voice, but the power to change health profiles remains an elusive goal.
Pharmaceutical Executive May 1, 2007 Humphrey Taylor	Commentary: The Sky is Falling! Healthcare systems in the developed world are in crisis. A permanent one. Patients and their physicians will always want more treatments than governments or employers are willing to pay for.
Pharmaceutical Executive August 1, 2014 William Looney	A Window on the Industry: The Emerging Pharma Leaders 2014 Pharm Exec's 2014 roster of emerging pharma leaders serves as a window on work in an industry that relies on human capital as the coinage of success.
Pharmaceutical Executive November 1, 2013 William Looney	Payers: Late for the Party? Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry.
Pharmaceutical Executive June 1, 2011	Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity?
Pharmaceutical Executive October 1, 2010	Nobel Laureate Elie Wiesel Exclusive Interview Ethical behavior can be a bridge-builder in an era where Big Pharma needs to find new partners. Is it up to the challenge?
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.
Pharmaceutical Executive July 1, 2013 William Looney	Talent, Terror, and the Turnaround We offer news on 15 new Emerging Pharma Leaders, business innovation, and terrorism threats to the pharmaceutical industry.
Pharmaceutical Executive April 1, 2011 William Looney	Platforms for Peerless Performance A true performance culture has to focus on the mundane as much as the sublime.
Food Processing December 2012 Suley Muratoglu	Marketplace Trends to Watch For in 2013: It's Time to Think Small Beverage manufacturers and all food processors must embrace the new, smaller American household.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Pharmaceutical Executive May 1, 2005 Marsha Meyer	Medical Education: Prevention Education Shifting the nation's healthcare paradigm from treating seniors' ills to preventing them will take the combined support of pharma companies, medical schools, continuing medical education (CME) providers, and clinicians.
Pharmaceutical Executive March 1, 2014 William Looney	The Community Ethic Regardless of how you define it, partnership is also an institutional necessity as big Pharma adjusts to disruptive changes in the way health services are financed and delivered.
Pharmaceutical Executive July 1, 2011 Mangesh Sai	What the 2011 Census of India Reveals for Pharma What India's latest census tells us about current and future pharma opportunities.
Chemistry World October 15, 2014 Rebecca Trager	Quotas proposed to back younger US researchers A US politician's plans to introduce quotas to ensure that the National Institutes of Health's grants go to younger researchers is receiving opposition from somewhat surprising quarters -- science advocacy groups.
Pharmaceutical Executive February 1, 2012 Sarah Krug	Introducing the 'Chief Patient Officer' Now is the time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust.
Pharmaceutical Executive January 1, 2012 Elys Roberts & Sarah Phillips	The Emergence of the Pro-Patient How can pharma embrace and interact with increasingly informed and demanding patients to bring positive outcomes for all?
Pharmaceutical Executive May 1, 2012 William Looney	Seeding Beyond the Base The pharmaceutical industry's reputation as a growth industry no one wants to pay for is more secure than ever.
Finance & Development September 1, 2006 Bloom & Canning	Booms, Busts, and Echoes Since 1870 death rates and birth rates have been declining in developed countries. Here's how the biggest demographic upheaval in history is affecting global economic development.
Reason December 2003 Julian Sanchez	Misreading Millennials There's little agreement on the political character of the largest U.S. demographic cohort since the baby boom. The Millennials serve as a political Rorschach test, with partisans of the left and the right each seeing their own proclivities as dominant.
Pharmaceutical Executive August 1, 2013 Peter Houston	The Case for Content Reaching skittish consumers through objective, story driven information is digital marketing's hottest digit. But applying this consumer phenomenon in Big Pharma presents some unique challenges.
Pharmaceutical Executive February 1, 2006 Chandler & Chicco	Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways
Pharmaceutical Executive September 1, 2005 Wolfgang Klietmann	Thought Leader: (Eco)systemic Change The author discusses how various players within the healthcare system interact.
Pharmaceutical Executive February 1, 2011 Jill Wechsler	The Building Block of Drug Discovery With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?
Pharmaceutical Executive December 1, 2010	The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs.
Pharmaceutical Executive January 21, 2014 William Looney	For Russia -- Tough Love Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exist.
Job Journal December 12, 2010	Emerging Careers in Science and Healthcare Technological innovations drive opportunities in the fields of science and healthcare.
Investment Advisor November 2006	Remarks by Chairman Ben S. Bernanke The Coming Demographic Transition: Will We Treat Future Generations Fairly? -- Over the next few decades, the U.S. population will grow significantly older, a development that will affect our society and our economy in many ways.
Pharmaceutical Executive September 1, 2010	Looking Beyond the Patent Cliff Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP.
Pharmaceutical Executive July 1, 2012 William Looney	Less, But Better Pharm Exec's 2012 roster of Emerging Leaders is not only a way to recognize a few individuals who've made a difference in their organizations. It also serves as a barometer to track larger changes in the workplace.
Pharmaceutical Executive July 1, 2009 Patrick Clinton	What to Buy In the long run, pharma wants to sell health, not just drugs.
Pharmaceutical Executive May 1, 2005 Ame Wadler	PR: In the Loop Pharma marketers can help doctors stay abreast of the news.
Information Today August 2, 2012	Census Bureau API Lets Developers Create Custom Apps The U.S. Census Bureau launched a new online service that makes key demographic, socioeconomic, and housing statistics more accessible than ever before.
Pharmaceutical Executive August 1, 2012 Pascheles & Bogan	The Ultimate Business Model: Planning that Thousand Year Future In an era where success is monitored and measured in microseconds, planning for the long term is increasingly seen as an abstract absurdity. Yet the principles of natural selection, when applied to the pharmaceutical business, suggest that a lasting business model is still possible.
Pharmaceutical Executive January 1, 2011	The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs
Fast Company March 2006 Andrew Zolli	Demographics: The Population Hourglass The United States of 2016 will find itself in the throes of demographic shifts that will upend our political, economic, and technological priorities and redefine our markets.